Skip to main content
Caplight Logo









Eureka Therapeutics

Eureka Therapeutics

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://www.eurekatherapeutics.com/

Last Round

Grant

Jun 6, 2023

Total Funding Raised

$136.6M

Company Overview

Eureka Therapeutics is a biotechnology company that develops novel T-cell therapies and antibody-drug discovery technology for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

t-cell therapysolid tumor treatmentcell therapyartemis platformliver cancer therapycar-t therapyt-cell engineeringantibody discoverybiotechphage displayclinical-stage biotechcancer immunotherapytcr mimicdrug developmentnext-gen car-t

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eureka Therapeutics Comparables

Compare Eureka Therapeutics with similar companies based on industry and business-model similarity.

Eureka Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Crossbow Therapeutics
82%
Oricell Therapeutics
81%
A2 Biotherapeutics
80%

Eureka Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 6, 2023
Series EMar 17, 2020
Series DJan 22, 2018
Series CSep 23, 2014

Key People

Founding team and executive leadership

Vivien Chan

Chief Operating Officer

Executive Team

Eureka Therapeutics Investors

Notable investors and investment history

Eureka Therapeutics investors
InvestorRounds
Acorn Campus VenturesSeries D, Series C
Suma VentureSeries C, Series D
California Institute for Regenerative MedicineGrant
Yuan CapitalSeries D, Series C
Harbinger Venture CapitalSeries C, Series D
金浦产业投资基金管理有限公司Series D
Acorn Pacific VenturesSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 22, 2025

    Added Iwai Chem, a chemicals/distribution SMB, as a customer.

  • Aug 12, 2025

    William S. Solari III has joined the Board of Directors.

Eureka Therapeutics Filings

Explore SEC and related filing metadata, where available.

Eureka Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Eureka Therapeutics's valuation, stock price, and market status.

Is Eureka Therapeutics a public or private company?

Eureka Therapeutics is a private company.

What is the current stock price of Eureka Therapeutics?

Eureka Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Eureka Therapeutics worth (valuation)?

Valuation information for Eureka Therapeutics is not publicly available.

Can I buy Eureka Therapeutics stock?

Eureka Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Eureka Therapeutics's last funding round?

Eureka Therapeutics's most recent funding round was Grant on June 6, 2023.

Who are the main investors in Eureka Therapeutics?

Key investors in Eureka Therapeutics include Yuan Capital, Acorn Pacific Ventures.

Will Eureka Therapeutics IPO soon?

No public IPO plans have been announced for Eureka Therapeutics.

How can I track Eureka Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Eureka Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEmeryville, California
Employee Range48
Year Founded2006
Last FundingJun 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?